vs
Everus Construction Group, Inc.（ECG）とRevvity（RVTY）の財務データ比較。上の社名をクリックして会社を切り替えられます
Everus Construction Group, Inc.の直近四半期売上が大きい（$1.0B vs $772.1M、Revvityの約1.3倍）。Revvityの純利益率が高く（12.7% vs 5.5%、差は7.3%）。Everus Construction Group, Inc.の前年同期比売上増加率が高い（33.2% vs 5.9%）。Revvityの直近四半期フリーキャッシュフローが多い（$161.8M vs $23.5M）。過去8四半期でEverus Construction Group, Inc.の売上複合成長率が高い（27.1% vs 9.0%）
レブィティ（Revvity, Inc.）は米国のライフサイエンス・診断事業を手がける企業で、製薬およびバイオテクノロジー業界を主な顧客とし、特に新たな細胞治療や遺伝子治療の開発に関連するサービス・製品を提供している。前身は多岐にわたる事業を展開してきた老舗企業パーキンエルマーである。
ECG vs RVTY — 直接比較
売上が大きい
ECG
1.3倍大きい
$772.1M
売上成長率が高い
ECG
+27.3%の差
5.9%
純利益率が高い
RVTY
純利益率が7.3%高い
5.5%
フリーキャッシュフローが多い
RVTY
FCF $138.3M多い
$23.5M
2年売上CAGRが高い
ECG
2年複合成長率
9.0%
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $1.0B | $772.1M |
| 純利益 | $55.3M | $98.4M |
| 粗利率 | 11.6% | — |
| 営業利益率 | 6.8% | 14.5% |
| 純利益率 | 5.5% | 12.7% |
| 売上前年比 | 33.2% | 5.9% |
| 純利益前年比 | 60.4% | 3.9% |
| EPS（希薄化後） | $1.09 | $0.86 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上ECGRVTY
| Q4 25 | $1.0B | $772.1M | ||
| Q3 25 | $986.8M | $698.9M | ||
| Q2 25 | $921.5M | $720.3M | ||
| Q1 25 | $826.6M | $664.8M | ||
| Q4 24 | $759.6M | $729.4M | ||
| Q3 24 | $761.0M | $684.0M | ||
| Q2 24 | $703.4M | $691.7M | ||
| Q1 24 | $625.7M | $649.9M |
純利益ECGRVTY
| Q4 25 | $55.3M | $98.4M | ||
| Q3 25 | $57.0M | $46.7M | ||
| Q2 25 | $52.8M | $53.9M | ||
| Q1 25 | $36.7M | $42.2M | ||
| Q4 24 | $34.5M | $94.6M | ||
| Q3 24 | $41.8M | $94.4M | ||
| Q2 24 | $39.0M | $55.4M | ||
| Q1 24 | $28.2M | $26.0M |
粗利率ECGRVTY
| Q4 25 | 11.6% | — | ||
| Q3 25 | 12.6% | 53.6% | ||
| Q2 25 | 13.0% | 54.5% | ||
| Q1 25 | 11.2% | 56.5% | ||
| Q4 24 | 11.4% | — | ||
| Q3 24 | 11.8% | 56.3% | ||
| Q2 24 | 12.6% | 55.7% | ||
| Q1 24 | 11.9% | 54.6% |
営業利益率ECGRVTY
| Q4 25 | 6.8% | 14.5% | ||
| Q3 25 | 7.3% | 11.7% | ||
| Q2 25 | 7.9% | 12.6% | ||
| Q1 25 | 6.2% | 10.9% | ||
| Q4 24 | 6.1% | 16.3% | ||
| Q3 24 | 7.1% | 14.3% | ||
| Q2 24 | 7.3% | 12.4% | ||
| Q1 24 | 6.2% | 6.8% |
純利益率ECGRVTY
| Q4 25 | 5.5% | 12.7% | ||
| Q3 25 | 5.8% | 6.7% | ||
| Q2 25 | 5.7% | 7.5% | ||
| Q1 25 | 4.4% | 6.4% | ||
| Q4 24 | 4.5% | 13.0% | ||
| Q3 24 | 5.5% | 13.8% | ||
| Q2 24 | 5.5% | 8.0% | ||
| Q1 24 | 4.5% | 4.0% |
EPS（希薄化後）ECGRVTY
| Q4 25 | $1.09 | $0.86 | ||
| Q3 25 | $1.11 | $0.40 | ||
| Q2 25 | $1.03 | $0.46 | ||
| Q1 25 | $0.72 | $0.35 | ||
| Q4 24 | $0.68 | $0.77 | ||
| Q3 24 | $0.82 | $0.77 | ||
| Q2 24 | $0.76 | $0.45 | ||
| Q1 24 | $0.55 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | — | $919.9M |
| 総負債低いほど良い | $281.5M | — |
| 株主資本純資産 | $629.8M | $7.3B |
| 総資産 | $1.7B | $12.2B |
| 負債/資本比率低いほどレバレッジが低い | 0.45× | — |
8四半期トレンド — 暦四半期で整列
現金・短期投資ECGRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $553.0K | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
総負債ECGRVTY
| Q4 25 | $281.5M | — | ||
| Q3 25 | $285.1M | — | ||
| Q2 25 | $288.6M | — | ||
| Q1 25 | $292.1M | — | ||
| Q4 24 | $295.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
株主資本ECGRVTY
| Q4 25 | $629.8M | $7.3B | ||
| Q3 25 | $573.0M | $7.4B | ||
| Q2 25 | $514.4M | $7.6B | ||
| Q1 25 | $460.2M | $7.6B | ||
| Q4 24 | $422.6M | $7.7B | ||
| Q3 24 | $453.3M | $7.9B | ||
| Q2 24 | $490.0M | $7.9B | ||
| Q1 24 | $464.3M | $7.8B |
総資産ECGRVTY
| Q4 25 | $1.7B | $12.2B | ||
| Q3 25 | $1.6B | $12.1B | ||
| Q2 25 | $1.5B | $12.4B | ||
| Q1 25 | $1.4B | $12.4B | ||
| Q4 24 | $1.3B | $12.4B | ||
| Q3 24 | $1.3B | $12.8B | ||
| Q2 24 | — | $13.4B | ||
| Q1 24 | — | $13.4B |
負債/資本比率ECGRVTY
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.56× | — | ||
| Q1 25 | 0.63× | — | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $48.2M | $182.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $23.5M | $161.8M |
| FCFマージンFCF / 売上 | 2.3% | 21.0% |
| 設備投資強度設備投資 / 売上 | 2.4% | 2.6% |
| キャッシュ転換率営業CF / 純利益 | 0.87× | 1.85× |
| 直近12ヶ月FCF直近4四半期 | $90.0M | $509.4M |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローECGRVTY
| Q4 25 | $48.2M | $182.0M | ||
| Q3 25 | $76.2M | $138.5M | ||
| Q2 25 | $25.3M | $134.3M | ||
| Q1 25 | $7.1M | $128.2M | ||
| Q4 24 | — | $174.2M | ||
| Q3 24 | $78.9M | $147.9M | ||
| Q2 24 | — | $158.6M | ||
| Q1 24 | $21.9M | $147.6M |
フリーキャッシュフローECGRVTY
| Q4 25 | $23.5M | $161.8M | ||
| Q3 25 | $65.7M | $120.0M | ||
| Q2 25 | $12.3M | $115.5M | ||
| Q1 25 | $-11.4M | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | $60.9M | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | $12.6M | $129.7M |
FCFマージンECGRVTY
| Q4 25 | 2.3% | 21.0% | ||
| Q3 25 | 6.7% | 17.2% | ||
| Q2 25 | 1.3% | 16.0% | ||
| Q1 25 | -1.4% | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | 8.0% | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | 2.0% | 20.0% |
設備投資強度ECGRVTY
| Q4 25 | 2.4% | 2.6% | ||
| Q3 25 | 1.1% | 2.6% | ||
| Q2 25 | 1.4% | 2.6% | ||
| Q1 25 | 2.2% | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | 2.4% | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | 1.5% | 2.7% |
キャッシュ転換率ECGRVTY
| Q4 25 | 0.87× | 1.85× | ||
| Q3 25 | 1.34× | 2.97× | ||
| Q2 25 | 0.48× | 2.49× | ||
| Q1 25 | 0.19× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 1.89× | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | 0.77× | 5.67× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ECG
| Commercial | $594.5M | 59% |
| Utility | $203.5M | 20% |
| Industrial | $82.8M | 8% |
| Institutional | $66.1M | 7% |
| Service And Other | $28.4M | 3% |
| Transportation | $24.2M | 2% |
| Renewables | $19.8M | 2% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
